Search research articles
Contact Us
Filters
Showing results (11-20 of 254) with videos related to
Page
of 26
Sort By:
Bulletin Du Cancer
|
July 9, 2004
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
Critical Reviews in Oncology/Hematology
|
August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
Mario Campone, Philippe Juin, Fabrice André, et al.
Bulletin Du Cancer
|
May 19, 2005
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
La Revue Du Praticien
|
July 18, 2008
[Adjuvant therapies: the example of breast cancer]
Thomas Bachelot, Jean-Paul Guastalla, Isabelle Ray-Coquard
Frontiers in Oncology
|
November 7, 2025
Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports
Zelmira Ballatore, Helene Vanacker, Rita Chiari, et al.
Bulletin Du Cancer
|
September 13, 2007
[Angiogenesis and breast cancer]
Thomas Bachelot, Isabelle Ray-Coquard, Philippe Cassier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2013
Reply to J.-H. Choi et al
Thomas Bachelot, Claire Cropet, Isabelle Ray-Coquard, et al.
Mutagenesis
|
February 18, 2015
Therogenetics: transferring GWAS technology to the clinic
David G Cox, Pierre-Etienne Heudel, Olivier Trédan, et al.
The Lancet. Oncology
|
January 2, 2013
Brain metastases from HER2-positive breast cancer - authors' reply
Thomas Bachelot, Claire Cropet, Véronique Diéras, et al.
Cancer Treatment Reviews
|
April 6, 2013
mTOR inhibitors in advanced breast cancer: ready for prime time?
Lesley-Ann Martin, Fabrice André, Mario Campone, et al.
Page
of 26
Search research articles
Search
Showing results (11-20 of 254) with videos related to
Sort By:
Page
of 26
Bulletin Du Cancer
|
July 9, 2004
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
Critical Reviews in Oncology/Hematology
|
August 6, 2010
Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
Mario Campone, Philippe Juin, Fabrice André, et al.
Bulletin Du Cancer
|
May 19, 2005
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
La Revue Du Praticien
|
July 18, 2008
[Adjuvant therapies: the example of breast cancer]
Thomas Bachelot, Jean-Paul Guastalla, Isabelle Ray-Coquard
Frontiers in Oncology
|
November 7, 2025
Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports
Zelmira Ballatore, Helene Vanacker, Rita Chiari, et al.
Bulletin Du Cancer
|
September 13, 2007
[Angiogenesis and breast cancer]
Thomas Bachelot, Isabelle Ray-Coquard, Philippe Cassier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2013
Reply to J.-H. Choi et al
Thomas Bachelot, Claire Cropet, Isabelle Ray-Coquard, et al.
Mutagenesis
|
February 18, 2015
Therogenetics: transferring GWAS technology to the clinic
David G Cox, Pierre-Etienne Heudel, Olivier Trédan, et al.
The Lancet. Oncology
|
January 2, 2013
Brain metastases from HER2-positive breast cancer - authors' reply
Thomas Bachelot, Claire Cropet, Véronique Diéras, et al.
Cancer Treatment Reviews
|
April 6, 2013
mTOR inhibitors in advanced breast cancer: ready for prime time?
Lesley-Ann Martin, Fabrice André, Mario Campone, et al.
Page
of 26